Focus Partners Advisor Solutions Boosts Neurocrine Biosciences Stake

Investment firm increases holding in biopharmaceutical company by over 150%

Published on Mar. 6, 2026

Got story updates? Submit your updates here. ›

Focus Partners Advisor Solutions LLC, an institutional investor, has increased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 152.5% in the third quarter, according to a recent SEC filing. The firm now owns 13,263 shares of the company's stock, valued at $1.945 million.

Why it matters

Neurocrine Biosciences is a prominent biopharmaceutical company focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. The increase in ownership by Focus Partners Advisor Solutions suggests the firm sees significant potential in Neurocrine's pipeline and future growth prospects.

The details

According to the 13F filing, Focus Partners Advisor Solutions purchased an additional 8,011 shares of Neurocrine Biosciences during the third quarter, bringing its total holdings to 13,263 shares. This represents a 152.5% increase in the firm's position in the company. Neurocrine Biosciences' lead marketed product is Ingrezza, which is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.

  • Focus Partners Advisor Solutions filed the 13F report disclosing the increased stake in Neurocrine Biosciences in the 3rd quarter of 2026.

The players

Focus Partners Advisor Solutions LLC

An institutional investment firm that has increased its stake in Neurocrine Biosciences by over 150% in the third quarter.

Neurocrine Biosciences, Inc.

A biopharmaceutical company focused on developing treatments for neurological, endocrine and neuropsychiatric disorders, and the maker of the drug Ingrezza for tardive dyskinesia.

Got photos? Submit your photos here. ›

The takeaway

The significant increase in ownership by Focus Partners Advisor Solutions in Neurocrine Biosciences suggests the investment firm sees strong potential in the biopharmaceutical company's future growth and product pipeline, particularly its lead drug Ingrezza for tardive dyskinesia.